BioCryst Pharma - Public Comps and Valuation Multiples

BioCryst Pharma Overview

About BioCryst Pharma

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

Founded

1991

HQ

Employees

580

Website

biocryst.com

Sectors

Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $618M

LTM EBITDA $94.3M

EV

$1.8B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

BioCryst Pharma Financials

As of December 2025, BioCryst Pharma reported last 12-month revenue of $618M and EBITDA of $94.3M.

In the same period, BioCryst Pharma generated $604M in LTM gross profit and $27.6M in net income.

See BioCryst Pharma valuation multiples based on analyst estimates

BioCryst Pharma P&L

In the most recent fiscal year, BioCryst Pharma reported revenue of $451M and EBITDA of $12.8M.

BioCryst Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX

See BioCryst Pharma valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue	$618M	XXX	$451M	XXX	XXX	XXX
Gross Profit	$604M	XXX	$438M	XXX	XXX	XXX
Gross Margin	98%	XXX	97%	XXX	XXX	XXX
EBITDA	$94.3M	XXX	$12.8M	XXX	XXX	XXX
EBITDA Margin	15%	XXX	3%	XXX	XXX	XXX
EBIT	$118M	XXX	-$2.5M	XXX	XXX	XXX
EBIT Margin	19%	XXX	-1%	XXX	XXX	XXX
Net Profit	$27.6M	XXX	-$88.9M	XXX	XXX	XXX
Net Margin	4%	XXX	-20%	XXX	XXX	XXX
Net Debt	XXX	XXX	$691M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for BioCryst Pharma including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $618M. EBITDA for the last twelve months was $94.3M. In the most recent fiscal year, BioCryst Pharma achieved $451M in revenue and $12.8M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2026)	Next Fiscal Year (2027)	Two Years Forward (2028)
Total Revenue	$618M	Analyst estimates available to subscribers	$451M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$604M	Analyst estimates available to subscribers	$438M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	97.7% gross margin	Analyst estimates available to subscribers	97.2% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$94.3M	Analyst estimates available to subscribers	$12.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	15.3% EBITDA margin	Analyst estimates available to subscribers	2.8% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$118M	Analyst estimates available to subscribers	-$2.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	19.0% EBIT margin	Analyst estimates available to subscribers	-0.6% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$27.6M	Analyst estimates available to subscribers	-$88.9M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	4.5% net profit margin	Analyst estimates available to subscribers	-19.7% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$691M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for BioCryst Pharma

This financial data table provides comprehensive performance metrics for BioCryst Pharma, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

BioCryst Pharma generated $618M in revenue over the last twelve months.
The company achieved $94.3M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $604M.
Net income over the last twelve months reached $27.6M.

Fiscal Year Performance

In the most recent fiscal year, BioCryst Pharma reported $451M in total revenue.
Fiscal year EBITDA was $12.8M.
The company maintained a gross profit margin of 97.2% in the most recent fiscal year.
EBITDA margin for the fiscal year was 2.8%.
Net profit margin reached -19.7% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for BioCryst Pharma. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

BioCryst Pharma Stock Performance

BioCryst Pharma has current market cap of $1.4B, and EV of $1.8B.

Market Cap Evolution

BioCryst Pharma Stock Data

As of January 19, 2026, BioCryst Pharma's stock price is $7.

See BioCryst Pharma trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$1.8B	$1.4B	XXX	XXX	XXX	XXX	$0.13

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

BioCryst Pharma Valuation Multiples

BioCryst Pharma's trades at 3.0x EV/Revenue multiple, and 19.5x EV/EBITDA.

See valuation multiples for BioCryst Pharma and 15K+ public comps

BioCryst Pharma Financial Valuation Multiples

As of January 19, 2026, BioCryst Pharma has market cap of $1.4B and EV of $1.8B.

Equity research analysts estimate BioCryst Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

BioCryst Pharma has a P/E ratio of 50.9x.

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Market cap (current)	$1.4B	XXX	$1.4B	XXX	XXX	XXX
EV (current)	$1.8B	XXX	$1.8B	XXX	XXX	XXX
EV/Revenue	3.0x	XXX	3.0x	XXX	XXX	XXX
EV/EBITDA	19.5x	XXX	19.5x	XXX	XXX	XXX
EV/EBIT	15.6x	XXX	15.6x	XXX	XXX	XXX
EV/Gross Profit	3.0x	XXX	n/a	XXX	XXX	XXX
P/E	50.9x	XXX	50.9x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-34.5x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get BioCryst Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

BioCryst Pharma Margins & Growth Rates

BioCryst Pharma's last 12 month revenue growth is 7%

BioCryst Pharma's revenue per employee in the last FY averaged $0.8M, while opex per employee averaged $0.8M for the same period.

BioCryst Pharma's rule of 40 is -28% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

BioCryst Pharma's rule of X is 33% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for BioCryst Pharma and other 15K+ public comps

BioCryst Pharma Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue Growth	7%	XXX	9%	XXX	XXX	XXX
EBITDA Margin	15%	XXX	15%	XXX	XXX	XXX
EBITDA Growth	-6%	XXX	n/a	XXX	XXX	XXX
Rule of 40	-28%	XXX	22%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	33%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.8M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.8M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	39%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	98%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial